Our 5th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress to be held on 26 - 29 October 2021 would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in the development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors.
- With more than 20 speakers across the world from pharma, bio-pharma and biotech companies, the congress will discuss the latest updates in the development of ADC’s, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy
- Meet and network with experts from leading universities and industry sharing their knowledge on Preclinical and Translational Immuno-Oncology Developments, NextGen CAR-T Cell Therapy, Immune Checkpoint Inhibitors, Monoclonal and Bispecific Antibodies and more.
- A platform to meet experts from Pharma, biopharma and biotech companies and increase your learning in Monoclonal and Bispecific Antibodies, Cell Therapy and Immune Checkpoint Inhibitors.
This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.
What to Expect
- Updates in development of ADC’s and Bispecific Ab’s
- Immune Checkpoint Inhibitors and Combinations
- Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
- Biomarkers and Personalized Medicine in IO
- CAR-T Cell therapy, TCR Based-Cell Therapy
- Tumor microenvironment and Oncolytic Viruses
- Exclusive conference to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
- Find out new case studies of immune-oncology projects in the development
- Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
- Explore the latest platforms and technologies on the market for development
- Discuss the best tool for your research in immune-oncology
- Share your work and achievements with your industry peers in the Poster Session
Senior Vice President, Global Medical Affairs, ,
Stefan Glück, MD, PhD, FRCPC is medical oncologist and currently is VP, Head Oncology franchise in Medical affairs at Regeneron. He leads a fast growing team of internal experts in the field of Hematology and Oncology. Prior to that he was V.P. Global Medical Affairs, at Celgene Corporation since October 2014 until December 2019. He oversaw oncology activities worldwide, as well as the Immuno-Oncology program in solid tumors and hematology. He also contributed to activities of Celgene around Early Assets.
He previously served as a Sylvester Professor in the Department of Medicine at Miller School of Medicine, University of Miami, Florida until September 2014. From 2003–2008, he was the Clinical Director of the Braman Family Breast Cancer Institute, and from January 2009 - December 2010 Assistant Director of the Sylvester Comprehensive Cancer Center and Associate Chief, Division Hematology & Medical Oncology. He has been a PI of 37 clinical studies of breast cancer in Miami, as well as investigator in numerous scientific, translational projects. Before his move to Miami, Dr. Glück was Director of Southern Alberta Breast Cancer Program at the Tom Baker Cancer Center, a Professor in the departments of oncology, medicine, pharmacology & therapeutics at the University of Calgary, Alberta, Canada, and Deputy Head, Dept. of Oncology at the University of Calgary. He completed his medical studies at the Free University of West Berlin, Germany. The internship in Berlin was followed by residency in internal medicine and fellowship in hematology at the Heinrich Heine Universität in Düsseldorf, Germany, and a medical oncology & bone marrow transplant fellowship at the Princess Margaret Hospital, University of Toronto, Canada.
Dr. Glück was presented the “America’s Top Oncologists” 2008 award from Consumers’ Research Council of America, as well as “Best Doctors in America” honor since 2006, and has annually earned that prestige every year to 2014. This award was warranted after less than 3 years of working in the United States.
Professor, Cancer Immunotherapy, ,
University of Nottingham, UK
Lindy is Professor of Cancer Immunotherapy at the University of Nottingham and CSO of Scancell Ltd. She has developed a panel of mabs recognised tumour associated glycans and has pioneered an new antibody engineering technology which enhances the avidity of mabs, termed Avidimabs. This has been applied to the anti-glycan mabs resulting in direct killing mabs. These mAbs are also good at drug delivery making strong ADCs with duocarmycin and PBD payloads. She has developed two vaccine platforms ImmunoBodyTM and ModitopeTM which induce potent killer CD8 T cells and and cytotoxic CD4 T cells to post-translational modifications respectively. The first ImmunoBodyTM, SCIB1, has completed a phase I/II clinical trial in which 14/16 patients with melanoma have been disease free for five years. The first product from the ModitopeTM platform will enter the clinic next year. Lindy has over 150 peer reviewed publications and is also the inventor on 66 patents. She was award of the Waldenstrom prize for cancer Immunotherapy in 2019.
CSO, Director, VP, Head, Senior Investigator, Manager, Principal Scientist, Team Leader, Group Leaders, Professors, Assistant Professors, Research fellows, PhDs working on
- Monoclonal and Bispecific Antibodies
- Cell Therapy
- Immune Checkpoint Inhibitors